Score Your Stock

US stock · figures in US dollars · scored on full-year results

Idexx Laboratories IDEXX Laboratories, Inc.

IDXX · Healthcare · Diagnostics & Research
Top 30% of scored stocks
OkayTop 30% of scored stocks
Weak Spot

Idexx Laboratories scores 61/100 on fundamentals: in the top 30% of 503 scored S&P 500 stocks. Its strongest area is Risk (92/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.

Best
Risk 92
Weakest
Price 0
  • Carries a Weak Spot flag

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 43.4b#257 of 503 in the S&P 500EPSUS$ 14.23P/E38.2×✗ vs sector median 29.6×P/B27×✗ vs sector median 3.7×Div yieldNo dividends paidBottom 9% in the S&P 50052w range · 19% of range500.61769.98
as of 31 Oct 2026

Nearby peers

Ranks #20 of 60 in Healthcare by score

#1Universal Health Services79#18Medtronic62#19Cardinal Health61
#20Idexx Laboratories61
#21McKesson59#22Agilent Technologies57

One-Minute Summary

Why Idexx Laboratories scores 61

An expensively priced stock, but price fairness needs attention.

What looks good
What to watch

Business Strength

90
Why 90?
Pillar score: (2 + 1 + 2 + 2 + 2) = 9 of 10 points → 90
Return on Equity (ROE)71%Strong4-Year Revenue Growth+8%/yrOkay4-Year Profit Growth+10%/yrStrongNet Profit Margin25%StrongQuarterly Momentum+13%Strong
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +34.9%Equity ↑ +8.6%ROE % 70.7%
Net ProfitEquityROE %
845m888m1.1b1.1b1.5b1.6b1.6b1.6b202320242025TTM56.9%55.7%66%70.7%

Revenue & Net Profit, with Net Margin

Revenue ↑ +24.4%Net Profit ↑ +34.9%Net Margin % 25%
RevenueNet ProfitNet Margin %
3.7b3.9b4.3b4.6b845m888m1.1b1.1b202320242025TTM23.1%22.8%24.6%25%

Sales grew about 24.4% over 4 years: customers keep spending more with this company.

Profit climbed about 34.9% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +24.7%Net Profit ↑ +45.4%Net Margin % 27.8%
RevenueNet ProfitNet Margin %
976m954m998m1.1b1.1b1.1b1.1b1.2b233m216m243m294m275m248m278m338mQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'2623.9%22.6%24.3%26.5%24.8%22.8%24.4%27.8%
▲▲▬▲▲▲▲▲

Sales grew about 24.7% over the last 8 quarters: customers keep spending more with this company.

Profit grew about 45.4% over the last 8 quarters: the business is keeping more of what it earns.

Why 67?
Pillar score: (1 + 1 + 2) = 4 of 6 points → 67
Debt-to-Equity0.7×OkayCurrent Ratio1.2×OkayInterest Coverage38.7×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt → +2.7%Equity ↑ +8.6%D/E 0.7×
Total DebtEquityD/E
1.1b987m976m1.1b1.5b1.6b1.6b1.6b202320242025TTM0.7×0.6×0.6×0.7×

Borrowings have stayed roughly level: manageable, as long as profits stay healthy.

Short-term assets vs bills, with Current Ratio

Current Assets → +0.9%Current Liabilities ↑ +35.3%Current Ratio 1.2×
Current AssetsCurrent LiabilitiesCurrent Ratio
1.5b1.4b1.4b1.5b952m1.1b1.1b1.3b202320242025TTM1.6×1.3×1.2×1.2×
Why 50?
Pillar score: (0 + 2 + 2 + 0) = 4 of 8 points → 50
Dividend QualityNo dividends paidWeak
Payout ratio: 0%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsShrinking & thinWeak
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +51.3%Free CF ↑ +60.1%
Operating CFFree CF
907m929m1.2b1.4b773m798m1.0b1.2b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↓ -56.6%Short-Term Debt ↑ +105.8%Total Debt → +2.7%
CashShort-Term DebtTotal Debt
454m288m180m197m325m418m473m669m1.1b987m976m1.1b202320242025TTM

Dividends per Share, with Yield

DPS (cents) → +0%Yield % 0%
DPS (cents)Yield %
000020222023202420250%0%0%0%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 0?
Pillar score: (0 + 0 + 0) = 0 of 6 points → 0
P/E Ratio38.2×WeakP/B Ratio27×WeakPEG Ratio3.6Weak
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 752.88US$ 628.79US$ 504.70Oct '25Feb '26Jun '26Oct '26

The share price is down about 12.4% over the past year.

Why 92?
Pillar score: (2 + 1 + 2 + 2 + 2 + 2) = 11 of 12 points → 92
Earnings ConsistencySteadyStrongDebt Trend (4yr)StableOkayShare Count Trend (4yr)-2%/yrStrongInventory vs Sales (4yr)-6.6 pp/yr vs salesStrongAsset Turnover Trend (4yr)+17.8%StrongQuarterly Consistency0 of 4 quarters downStrong
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +24.4%Inventory → +3%Inv. % of Rev. 8.6%
RevenueInventoryInv. % of Rev.
3.7b3.9b4.3b4.6b380m382m378m392m202320242025TTM10.4%9.8%8.8%8.6%
Ranks #20 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#18Medtronic62#19Cardinal Health61
#20Idexx Laboratories (you)61
#21McKesson59#22Agilent Technologies57

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 4.6bUS$ 1.1bUS$ 1.4bUS$ 1.2bUS$ -134.4mUS$ 196.9mUS$ 1.1bUS$ 669.0mUS$ 1.6bUS$ 1.5bUS$ 1.3bUS$ 3.4bUS$ 1.8bUS$ 391.6m-71%25%0.7×1.2×38.7×----
2025US$ 4.3bUS$ 1.1bUS$ 1.2bUS$ 1.0bUS$ -138.2mUS$ 180.1mUS$ 976.1mUS$ 473.0mUS$ 1.6bUS$ 1.4bUS$ 1.1bUS$ 3.4bUS$ 1.7bUS$ 377.8mUS$ 0.0m66%25%0.6×1.2×35.1×0%50.4×33.3×3.2
2024US$ 3.9bUS$ 887.9mUS$ 929.0mUS$ 798.1mUS$ -130.9mUS$ 288.3mUS$ 986.9mUS$ 417.8mUS$ 1.6bUS$ 1.4bUS$ 1.1bUS$ 3.3bUS$ 1.7bUS$ 381.9mUS$ 0.0m56%23%0.6×1.3×36.6×0%38.2×21.3×2.7
2023US$ 3.7bUS$ 845.0mUS$ 906.5mUS$ 772.9mUS$ -133.6mUS$ 453.9mUS$ 1.1bUS$ 325.0mUS$ 1.5bUS$ 1.5bUS$ 951.5mUS$ 3.3bUS$ 1.8bUS$ 380.3mUS$ 0.0m57%23%0.7×1.6×26.5×0%54.5×31.0×2.2